Literature DB >> 18026827

Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.

Marion Deon1, Mariana Pires Garcia, Angela Sitta, Alethéa G Barschak, Daniella M Coelho, Graziela O Schimit, Maiara Pigatto, Laura B Jardim, Moacir Wajner, Roberto Giugliani, Carmen R Vargas.   

Abstract

X-linked adrenoleukodystrophy (X-ALD) is an inherited disorder of peroxisomal metabolism, biochemically characterized by deficient beta-oxidation of saturated very long chain fatty acids (VLCFA). The consequent accumulation of these fatty acids in different tissues and in biological fluids is associated with a progressive central and peripheral demyelination, as well as with adrenocortical insufficiency and hypogonadism. Seven variants of this disease have been described, cerebral childhood being the most frequent. The recommended therapy consists of the use of the glyceroltrioleate/glyceroltrierucate mixture known as Lorenzo's Oil (LO), combined with a VLCFA-poor diet, but only in asymptomatic patients will this treatment prevent the progression of the symptomatology. In the present study we evaluated the biochemical course of patients with cerebral childhood (CCER) and asymptomatic clinical forms of X-ALD treated with LO associated with a VLCFA-restricted diet. We observed that hexacosanoic acid plasma concentrations and hexacosanoic/docosanoic ratio were significantly reduced in CCER patients during treatment when compared with diagnosis. Hexacosanoic acid plasma level was significantly reduced when compared with that at diagnosis and achieved the normal levels only in asymptomatic patients under LO treatment. In asymptomatic patients the magnitude of hexacosanoic acid decrease was higher than that of the CCER patients. These results show the good biochemical response of LO treatment in asymptomatic X-ALD patients. It is possible to suppose that this could be correlated with the prevention of the appearance of neurological signals in this group of patients treated with LO.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18026827     DOI: 10.1007/s11011-007-9079-9

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  12 in total

1.  Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil".

Authors:  B M van Geel; J Assies; E B Haverkort; J H Koelman; B Verbeeten; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

Review 2.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 3.  Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy.

Authors:  H W Moser
Journal:  Brain       Date:  1997-08       Impact factor: 13.501

4.  Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening.

Authors:  Prachi Dubey; Gerald V Raymond; Ann B Moser; Sidharth Kharkar; Lena Bezman; Hugo W Moser
Journal:  J Pediatr       Date:  2005-04       Impact factor: 4.406

Review 5.  X-linked adrenoleukodystrophy: therapeutic approaches to distinct phenotypes.

Authors:  Asif Mahmood; Prachi Dubey; Hugo W Moser; Ann Moser
Journal:  Pediatr Transplant       Date:  2005-12

6.  Glycerol trioleate/glycerol trierucate therapy in X-linked adrenoleukodystrophy: saturated and unsaturated fatty acids in blood cells. Implications for the follow-up.

Authors:  M Ruiz; T Pampols; M Girós
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

7.  The clinical course of childhood and adolescent adrenoleukodystrophy before and after Lorenzo's oil.

Authors:  Y Suzuki; A Imamura; N Shimozawa; N Kondo
Journal:  Brain Dev       Date:  2001-03       Impact factor: 1.961

8.  Neurophysiologic follow-up of long-term dietary treatment in adult-onset adrenoleukodystrophy.

Authors:  D Restuccia; V Di Lazzaro; M Valeriani; A Oliviero; D Le Pera; C Barba; M Cappa; E Bertini; M Di Capua; P Tonali
Journal:  Neurology       Date:  1999-03-10       Impact factor: 9.910

9.  Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters.

Authors:  G C Korenke; D H Hunneman; J Kohler; S Stöckler; K Landmark; F Hanefeld
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

Review 10.  Progress in X-linked adrenoleukodystrophy.

Authors:  Hugo Moser; Prachi Dubey; Ali Fatemi
Journal:  Curr Opin Neurol       Date:  2004-06       Impact factor: 5.710

View more
  8 in total

1.  ABCD1 deletion-induced mitochondrial dysfunction is corrected by SAHA: implication for adrenoleukodystrophy.

Authors:  Mauhamad Baarine; Craig Beeson; Avtar Singh; Inderjit Singh
Journal:  J Neurochem       Date:  2015-01-13       Impact factor: 5.372

2.  Female carriers of X-chromosomal adrenoleukodystrophy: a major differential diagnosis in progressive myelopathy.

Authors:  Anne-Katrin Guettsches; Alma Kuechler; Andreas Gal; Werner Schmitz; Martin Tegenthoff; Matthias Vorgerd
Journal:  J Neurol       Date:  2010-03-02       Impact factor: 4.849

3.  Effect of Lorenzo's Oil on Hepatic Gene Expression and the Serum Fatty Acid Level in abcd1-Deficient Mice.

Authors:  Masashi Morita; Ayako Honda; Akira Kobayashi; Yuichi Watanabe; Shiro Watanabe; Kosuke Kawaguchi; Shigeo Takashima; Nobuyuki Shimozawa; Tsuneo Imanaka
Journal:  JIMD Rep       Date:  2017-05-31

4.  Essential fatty acid profiling for routine nutritional assessment unmasks adrenoleukodystrophy in an infant with isovaleric acidaemia.

Authors:  R Bonilla Guerrero; L A Wolfe; N Payne; S Tortorelli; D Matern; P Rinaldo; D Gavrilov; M Melan; M He; S J Steinberg; G V Raymond; J Vockley; K M Gibson
Journal:  J Inherit Metab Dis       Date:  2008-12-16       Impact factor: 4.982

5.  Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.

Authors:  Jaspreet Singh; Mushfiquddin Khan; Inderjit Singh
Journal:  J Lipid Res       Date:  2008-08-21       Impact factor: 5.922

6.  Fast diffusion of very long chain saturated fatty acids across a bilayer membrane and their rapid extraction by cyclodextrins: implications for adrenoleukodystrophy.

Authors:  Biju K Pillai; Ravi Jasuja; Jeffrey R Simard; James A Hamilton
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

7.  Oxidative Imbalance, Nitrative Stress, and Inflammation in C6 Glial Cells Exposed to Hexacosanoic Acid: Protective Effect of N-acetyl-L-cysteine, Trolox, and Rosuvastatin.

Authors:  Desirèe Padilha Marchetti; Luiza Steffens; Carlos E Jacques; Gilian B Guerreiro; Caroline P Mescka; Marion Deon; Daniella M de Coelho; Dinara J Moura; Alice G Viario; Fernanda Poletto; Adriana S Coitinho; Laura B Jardim; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2018-10-09       Impact factor: 5.046

8.  Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study.

Authors:  Vijitha K Senanayake; Wei Jin; Asuka Mochizuki; Bassirou Chitou; Dayan B Goodenowe
Journal:  BMC Neurol       Date:  2015-08-27       Impact factor: 2.474

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.